Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT006-AngQb in Healthy and Hypertensive Subjects
NCT00500786Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Nov 2004
- Primary completion
- Sep 2006
- Modality
- Recombinant Protein Vaccines
01
Overview
Phase 2, randomised, double-blind trial of CYT006-AngQb in essential hypertension (5 arms), sponsored by Cytos Biotechnology AG. Primary endpoint: Safety and Tolerability. Started Nov 2004; status: completed.
02
Drugs
CYT006-AngQb
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00500786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500786.